4DMedical Limited

4DMedical Limited develops advanced software for functional lung imaging and analysis. The company specializes in extracting quantified lung function data from standard imaging modalities (X-ray and CT) to enable non-invasive diagnosis and treatment planning. Core products include CT:VQ™ (FDA-cleared non-contrast CT ventilation/perfusion imaging), CT Lung Volume Analysis System (CT-LVAS), Lung Density Analysis, and XV Lung Volume Analysis. These solutions are designed for pulmonology, thoracic surgery, and VA healthcare settings, particularly for patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease, and veterans exposed to airborne toxins. The company's XV Technology platform provides breakthrough functional lung imaging capabilities. 4DMedical has obtained FDA clearance for CT:VQ™ and CE Mark approval for European commercialization as of March 2026. The software integrates with existing hospital imaging infrastructure and enables clinicians to quantify regional lung ventilation and perfusion without contrast agents. Target markets include academic medical centers, thoracic surgery programs, VA hospitals, and pulmonary clinics. The company participates in major medical conferences including the American Association for Thoracic Surgery (AATS) and American Thoracic Society (ATS).